Expert Consensus on Medication Therapy for Acid-related Diseases

doi:10.12114/j.issn.1007-9572.2026.0063

Abstract

Abstract:

Acid-related diseases are characterized by high incidence rates and significant disease burden. Excessive gastric acid secretion or heightened gastric acid sensitivity represents the common pathogenesis of these conditions, leading to the widespread application of the principle of "treating different diseases with the same therapy" in medication management. With growing concerns regarding the risks associated with inappropriate use of acid-suppressing drugs such as proton pump inhibitors, there is an urgent need to deepen the systematic understanding of medication therapy for acid-related diseases and to promote rational drug use. This consensus was developed by a multidisciplinary panel of experts in clinical medicine, pharmacy, and methodology. Based on evidence-based medicine, it provides a systematic elaboration on the classification of acid-related diseases, therapeutic drugs, diagnostic methods, and pharmaceutical care services. Additionally, it offers consensus recommendations and management strategies for key clinical issues encountered in practice. The release of this consensus is of great significance for establishing a medication therapy management system and promoting rational drug use for acid-related diseases.

Key words: Acid-related diseases, Pharmaceutical services, Medication therapy, Rational drug use, Expert consensus

摘要：

酸相关疾病发病率高，且高负担特征明显。胃酸分泌过多或胃酸高敏感是酸相关疾病的共同发病机制，在药物治疗方面，"异病同治"现象较为普遍。随着质子泵抑制剂等抑酸药物不合理使用风险日益受到关注，迫切需要加深对酸相关疾病药物治疗的系统性认识，促进合理用药。本共识通过组织临床医学、药学和方法学等多学科专家，基于循证医学证据，在酸相关疾病分类、治疗药物、诊断方法、药学服务等方面进行系统性阐述，并就实践中面临的主要临床问题进行共识和处置推荐。本共识的发布对国内酸相关疾病药物治疗管理体系建立、促进合理用药具有重要意义。

关键词: 酸相关疾病, 药学服务, 药学治疗, 合理用药, 专家共识

CLC Number:

R 95

China Pharmacological Society Committee on Drug-induced Diseases. Expert Consensus on Medication Therapy for Acid-related Diseases[J]. Chinese General Practice, 2026, 29(19): 2593-2607. DOI: 10.12114/j.issn.1007-9572.2026.0063.
中国药理学会药源性疾病专委会. 酸相关疾病药物治疗专家共识[J]. 中国全科医学, 2026, 29(19): 2593-2607. DOI: 10.12114/j.issn.1007-9572.2026.0063.

Figures/Tables 6

References 143

[1]	樊晓明. 酸相关性疾病[M]. 上海: 复旦大学出版社, 2011.
[2]	Eusebi L H, Cirota G G, Zagari R M, et al. Global prevalence of Barrett's oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and meta-analysis[J]. Gut, 2021, 70(3): 456-463. DOI: 10.1136/gutjnl-2020-321365.
[3]	Pasricha P J, Talley N J. Functional dyspepsia[J]. N Engl J Med, 2026, 394(2): 166-176. DOI: 10.1056/nejmcp2501860.
[4]	Lanas A, Chan F K L. Peptic ulcer disease[J]. Lancet, 2017, 390(10094): 613-624. DOI: 10.1016/s0140-6736(16)32404-7.
[5]	Yang H, Zhang M, Li H, et al. Prevalence of common upper gastrointestinal diseases in Chinese adults aged 18-64 years[J]. Sci Bull, 2024, 69(24): 3889-3898. DOI: 10.1016/j.scib.2024.07.048.
[6]	Long Y Q, Xu W L, Li L X, et al. Characteristics and risk factors of functional dyspepsia fulfilling the RomeⅣ criteria overlapping with gastroesophageal reflux disease, irritable bowel syndrome, and functional constipation in South China[J]. J Neurogastroenterol Motil, 2024, 30(2): 184-193. DOI: 10.5056/jnm23084.
[7]	Xiao Y L, Zhou L Y, Hou X H, et al. Chinese expert consensus on gastroesophageal reflux disease in 2020[J]. J Digest Diseases, 2021, 22(7): 376-389. DOI: 10.1111/1751-2980.13028.
[8]	Simadibrata D M, Syam A F, Lee Y Y. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: a systematic review and meta-analysis[J]. J Gastro And Hepatol, 2022, 37(12): 2217-2228.
[9]	Inatomi N, Matsukawa J, Sakurai Y, et al. Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases[J]. Pharmacol Ther, 2016, 168: 12-22.
[10]	Veettil S K, Sadoyu S, Bald E M, et al. Association of proton-pump inhibitor use with adverse health outcomes: a systematic umbrella review of meta-analyses of cohort studies and randomised controlled trials[J]. Brit J Clinical Pharma, 2022, 88(4): 1551-1566.
[11]	Chaudhry M, Elahi M, Ali Bukhari S H, et al. Long-term proton pump inhibitor use and the risk of kidney disease, dementia, and fractures: a systematic review[J]. Cureus, 2025, 17(8): e90627. DOI: 10.7759/cureus.90627.
[12]	Yadlapati R, Gyawali C P, Pandolfino J E, et al. AGA clinical practice update on the personalized approach to the evaluation and management of GERD: expert review[J]. Clin Gastroenterol Hepatol, 2022, 20(5): 984-994.e1. DOI: 10.1016/j.cgh.2022.01.025.
[13]	魏婷, 都赛飞, 刘斌, 等. 质子泵抑制剂预防药物性消化道损伤的临床指南/共识、系统评价/meta分析再评价[J]. 中国药房, 2021, 32(17): 7. DOI: 10.6039/j.issn.1001-0408.2021.17.13.
[14]	Kang C. Keverprazan hydrochloride: first approval[J]. Drugs, 2023, 83(7): 639-643. DOI: 10.1007/s40265-023-01865-w.
[15]	Shea B J, Reeves B C, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both[J]. BMJ, 2017: j4008. DOI: 10.1136/bmj.j4008.
[16]	Higgins J P T, Altman D G, Gotzsche P C, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials[J]. BMJ, 2011, 343: d5928. DOI: 10.1136/bmj.d5928.
[17]	Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9): 603-605.
[18]	Guyatt G H, Oxman A D, Vist G E, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ, 2008, 336(7650): 924-926. DOI: 10.1136/bmj.39489.470347.ad.
[19]	Chen Y L, Yang K H, Marušić A, et al. Ein instrument zur erstellung von leitlinienberichten: das RIGHT-statement[J]. Z Für Evidenz Fortbild Und Qual Im Gesundheitswes, 2017(127/128): 3-10. DOI: 10.1016/j.zefq.2017.10.008.
[20]	Drossman D. 罗马Ⅳ功能性胃肠病: 肠-脑互动异常[M]. 柯美云, 译. 北京: 科学出版社, 2016.
[21]	中华医学会消化病学分会胃肠动力学组, 大中华区消化动力联盟. 食管动态反流监测临床操作指南(成人)[J]. 中华消化杂志, 2021, 41(3): 149-151. DOI: 10.3760/cma.j.cn311367-20210114-00032.
[22]	中国医师协会消化医师分会胃食管反流病专业委员会. 中国高分辨率食管测压临床操作指南(成人)[J]. 中华消化杂志, 2020, 40(1):3-8. DOI: 10.3760/cma.j.issn.0254-1432.2020.01.002.
[23]	Pluchart H, Bailly S, Chanoine S, et al. Impact of polypharmacy and comorbidity on survival and systemic parenteral treatment administration in a cohort of hospitalized lung-cancer patients[J]. BMC Cancer, 2023, 23(1): 585.
[24]	梁淑红, 孟海阳, 孔凯, 等. 丙帕他莫相关术后肝酶异常:临床预测列线图模型研究[J]. 中国药学(英文版), 2025, 34(4):305-320. DOI: 10.5246/jcps.2025.04.025.
[25]	Common terminology criteria for adverse events (CTCAE)\| protocol development \| CTEP[EB/OL].(2017-07-01)[2025-08-18].
[26]	国家卫生健康委员会. 体重管理指导原则(2024年版)摘登[J]. 新医学, 2025, 56(6):627-629. DOI: 10.12464/j.issn.0253-9802.2025-0165.
[27]	国家卫生健康委办公厅. 国家卫生健康委办公厅关于印发医疗机构药学门诊服务规范等5项规范的通知[A/OL]. (2024-12-05)[2025-08-18].
[28]	Hammer J, Schmidt B. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough[J]. Aliment Pharmacol Ther, 2004, 19(10): 1105-1110.
[29]	Tutuian R, Castell D O. Nocturnal acid breakthrough-approach to management[J]. Med Gen Med, 2004, 6(4): 11.
[30]	Peghini P L, Katz P O, Castell D O. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects[J]. Gastroenterology, 1998, 115(6): 1335-1339. DOI: 10.1016/s0016-5085(98)70010-1.
[31]	Katz P O, Anderson C, Khoury R, et al. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors[J]. Aliment Pharmacol Ther, 1998, 12(12): 1231-1234.
[32]	Katz P O, Dunbar K B, Schnoll-Sussman F H, et al. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease[J]. Am J Gastroenterol, 2022, 117(1): 27-56.
[33]	Pan T, Wang Y, Guo Z, et al. Additional bedtime H₂-receptor antagonist for the control of nocturnal gastric acid breakthrough[J]. Cochrane Database Syst Rev, 2004(4): CD004275.
[34]	Katz P O, Koch F K, Ballard E D, et al. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms[J]. Aliment Pharmacol Ther, 2007, 25(2): 197-205. DOI: 10.1111/j.1365-2036.2006.03191.x.
[35]	Yang E, Kim S, Kim B, et al. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole[J]. Brit J Clinical Pharma, 2022, 88(7): 3288-3296. DOI: 10.1111/bcp.15268.
[36]	Zhou S F, Xie L J, Zhou C, et al. Keverprazan, a novel potassium-competitive acid blocker: single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects[J]. Eur J Pharm Sci, 2023, 190: 106578.
[37]	Zou S P, Ouyang M L, Cheng Q, et al. Acid-suppressive drugs: a systematic review and network meta-analysis of their nocturnal acid-inhibitory effect[J]. Pharmacotherapy, 2024, 44(2): 171-183. DOI: 10.1002/phar.2899.
[38]	Wang Y J, Dai X S, Zhang X X. Network meta-analysis of comparing different dosages of potassium-competitive acid blocker with proton-pump inhibitor in acid-related disorders[J]. Clin Transl Gastroenterol, 2024, 15(11): e00776. DOI: 10.14309/ctg.0000000000000776.
[39]	Dong Y Q, Xu H Y, Zhang Z H, et al. Comparative efficiency and safety of potassium competitive acid blockers versus Lansoprazole in peptic ulcer: a systematic review and meta-analysis[J]. Front Pharmacol, 2024, 14: 1304552. DOI: 10.3389/fphar.2023.1304552.
[40]	Ishida M, Tsuchiya M, Naito J, et al. Vonoprazan-associated nephrotoxicity: extensive real-world evidence from spontaneous adverse drug reaction reports[J]. Kidney Int, 2022, 102(3): 666-668.
[41]	Hwang S, Ko J W, Lee H, et al. Co-administration of vonoprazan, not tegoprazan, affects the pharmacokinetics of atorvastatin in healthy male subjects[J]. Front Pharmacol, 2021, 12: 754849. DOI: 10.3389/fphar.2021.754849.
[42]	Jankovic K, Gralnek I M, Awadie H. Emerging long-term risks of the use of proton pump inhibitors and potassium-competitive acid blockers[J]. Annu Rev Med, 2025, 76: 143-153. DOI: 10.1146/annurev-med-050223-112834.
[43]	Kushima R, Uemura N, Kinoshita Y, et al. ep1118: 4-year interim analysis results of vision trial: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis[J]. Gastroenterology, 2022, 162(7): S-1066-S-1067. DOI: 10.1016/s0016-5085(22)62550-2.
[44]	Aiba M, Tsutsumi Y, Jun N G, et al. Convulsive seizure due to hypomagnesemia caused by short-term vonoprazan intake[J]. Intern Med, 2022, 61(2): 237-240.
[45]	Okamoto M, Wakunami Y, Hashimoto K. Severe hypomagnesemia associated with the long-term use of the potassium-competitive acid blocker vonoprazan[J]. Intern Med, 2022, 61(1): 119-122.
[46]	Moayyedi P M, Lacy B E, Andrews C N, et al. ACG and CAG clinical guideline: management of dyspepsia[J]. Am J Gastroenterol, 2017, 112(7): 988-1013. DOI: 10.1038/ajg.2017.154.
[47]	Miwa H, Nagahara A, Asakawa A, et al. Evidence-based clinical practice guidelines for functional dyspepsia 2021[J]. J Gastroenterol, 2022, 57(2): 47-61. DOI: 10.1007/s00535-021-01843-7.
[48]	Ford A C, Moayyedi P, Black C J, et al. Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia[J]. Aliment Pharmacol Ther, 2021, 53(1): 8-21.
[49]	Zhou W, Li X, Huang Y, et al. Comparative efficacy and acceptability of psychotropic drugs for functional dyspepsia in adults: a systematic review and network meta-analysis[J]. Medicine, 2021, 100(20): e26046. DOI: 10.1097/md.0000000000026046.
[50]	Talley N J, Locke G R, Saito Y A, et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study[J]. Gastroenterology, 2015, 149(2): 340-349.e2. DOI: 10.1053/j.gastro.2015.04.020.
[51]	Luo L, Du L J, Shen J H, et al. Benefit of small dose antidepressants for functional dyspepsia: experience from a tertiary center in Eastern China[J]. Medicine, 2019, 98(41): e17501.
[52]	陈旻湖, 方秀才, 侯晓华, 等. 2022中国功能性消化不良诊治专家共识[J]. 胃肠病学, 2023, 28(8): 467-481.
[53]	Savarino E V, Barberio B, Scarpignato C, et al. Italian guidelines for the diagnosis and management of gastro-esophageal reflux disease: joint consensus from the Italian Societies of: gastroenterology and Endoscopy (SIGE), Neurogastroenterology and Motility (SINGEM), Hospital Gastroenterologists and Endoscopists (AIGO), Digestive Endoscopy (SIED), and General Medicine (SIMG)[J]. Dig Liver Dis, 2025, 57(8): 1550-1577. DOI: 10.1016/j.dld.2025.04.020.
[54]	Si X B, Huo L Y, Bi D Y, et al. Comparative efficacy of antidepressants for symptoms remission of gastroesophageal reflux: a Bayesian network meta-analysis of randomized controlled trials[J]. Turk J Gastroenterol, 2021, 32(10): 843-853.
[55]	Yeh J H, Chen C L, Sifrim D, et al. Central neuromodulators for patients with functional esophageal disorders: a systematic review and meta-analysis[J]. Dig Liver Dis, 2024, 56(10): 1675-1682.
[56]	Viazis N, Keyoglou A, Kanellopoulos A K, et al. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study[J]. Am J Gastroenterol, 2012, 107(11): 1662-1667.
[57]	Yamasaki T, Fass R. Reflux hypersensitivity: a new functional esophageal disorder[J]. J Neurogastroenterol Motil, 2017, 23(4): 495-503. DOI: 10.5056/jnm17097.
[58]	中国中西医结合学会消化系统疾病专业委员会. 胃食管反流病中西医结合诊疗专家共识(2025年)[J]. 中国中西医结合消化杂志, 2025, 33(3): 217-229.
[59]	陈旻湖, 李延青, 肖英莲, 等. 中国胃食管反流病诊疗规范[J]. 胃肠病学, 2023, 28(10): 597-607.
[60]	Reid M, Keniston A, Heller J C, et al. Inappropriate prescribing of proton pump inhibitors in hospitalized patients[J]. J Hosp Med, 2012, 7(5): 421-425. DOI: 10.1002/jhm.1901.
[61]	Savarino V, Marabotto E, Zentilin P, et al. Proton pump inhibitors: use and misuse in the clinical setting[J]. Expert Rev Clin Pharmacol, 2018, 11(11): 1123-1134. DOI: 10.1080/17512433.2018.1531703.
[62]	Sattayalertyanyong O, Thitilertdecha P, Auesomwang C. The inappropriate use of proton pump inhibitors during admission and after discharge: a prospective cross-sectional study[J]. Int J Clin Pharm, 2020, 42(1): 174-183. DOI: 10.1007/s11096-019-00955-8.
[63]	Alhazzani W, Guyatt G, Alshahrani M, et al. Withholding pantoprazole for stress ulcer prophylaxis in critically ill patients: a pilot randomized clinical trial and meta-analysis[J]. Crit Care Med, 2017, 45(7): 1121-1129. DOI: 10.1097/ccm.0000000000002461.
[64]	Kwok C S, Arthur A K, Anibueze C I, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis[J]. Am J Gastroenterol, 2012, 107(7): 1011-1019. DOI: 10.1038/ajg.2012.108.
[65]	Poly T N, Islam M M, Yang H C, et al. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies[J]. Osteoporos Int, 2019, 30(1): 103-114.
[66]	Dial S. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies[J]. Can Med Assoc J, 2004, 171(1): 33-38.
[67]	Buendgens L. Prevention of stress-related ulcer bleeding at the intensive care unit: risks and benefits of stress ulcer prophylaxis[J]. World J Crit Care Med, 2016, 5(1): 57. DOI: 10.5492/wjccm.v5.i1.57.
[68]	中国医师协会急诊医师分会. 中国急性胃黏膜病变急诊专家共识[J]. 中华急诊医学杂志, 2015, 24(10): 1072-1077.
[69]	柏愚, 李延青, 任旭, 等. 应激性溃疡防治专家建议(2015版)[J]. 中华医学杂志, 2015, 95(20): 1555-1557.
[70]	中华医学会外科学分会. 应激性黏膜病变预防与治疗:中国普通外科专家共识(2015)[J]. 中国实用外科杂志, 2015, 35(7): 728-730. DOI: 10.7504/CJPS.ISSN1005-2208.2015.07.10.
[71]	Lanza F L, Chan F K L, Quigley E M M. Guidelines for prevention of NSAID-related ulcer complications[J]. Am J Gastroenterol, 2009, 104(3): 728-738. DOI: 10.1038/ajg.2009.115.
[72]	Shalev A, Zahger D, Novack V, et al. Incidence, predictors and outcome of upper gastrointestinal bleeding in patients with acute coronary syndromes[J]. Int J Cardiol, 2012, 157(3): 386-390.
[73]	Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study[J]. BMJ, 2006, 333(7571): 726. DOI: 10.1136/bmj.38947.697558.ae.
[74]	Lanas A, García-Rodríguez L A, Arroyo M T, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations[J]. Gut, 2006, 55(12): 1731-1738. DOI: 10.1136/gut.2005.080754.
[75]	García Rodríguez L A, Lin K J, Hernández-Díaz S, et al. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications[J]. Circulation, 2011, 123(10): 1108-1115.
[76]	Yeomans N D, Lanas A I, Talley N J, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin[J]. Aliment Pharmacol Ther, 2005, 22(9): 795-801.
[77]	Jensen B E, Hansen J M, Junker A B, et al. High prevalence of ulcer bleeding risk factors in dual antiplatelet-treated patients after percutaneous coronary intervention[J]. Dan Med J, 2015, 62(6):A5092.
[78]	Taha A S, Angerson W J, Prasad R, et al. Clinical trial: the incidence and early mortality after peptic ulcer perforation, and the use of low-dose aspirin and nonsteroidal anti-inflammatory drugs[J]. Aliment Pharmacol Ther, 2008, 28(7): 878-885.
[79]	Devi D P, Sushma M, Guido S. Drug-induced upper gastrointestinal disorders requiring hospitalization: a five-year study in a South Indian hospital[J]. Pharmacoepidemiology and Drug, 2004, 13(12): 859-862. DOI: 10.1002/pds.988.
[80]	Jung D, Youn Y, Kim J H, et al. Factors influencing development of pain after gastric endoscopic submucosal dissection: a randomized controlled trial[J]. Endoscopy, 2015, 47(12): 1119-1123.
[81]	中国药学会医院药学专业委员会, 中华医学会临床药学分会, 质子泵抑制剂优化应用专家共识写作组. 质子泵抑制剂优化应用专家共识[J]. 中国医院药学杂志, 2020, 40(21): 2195-2213.
[82]	Fossmark R, Martinsen T C, Waldum H L. Adverse effects of proton pump inhibitors-evidence and plausibility[J]. Int J Mol Sci, 2019, 20(20): 5203. DOI: 10.3390/ijms20205203.
[83]	Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors[J]. Clin Endocrinol, 2008, 69(2): 338-341. DOI: 10.1111/j.1365-2265.2008.03194.x.
[84]	Lam J R, Schneider J L, Zhao W, et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B₁₂ deficiency[J]. Jama, 2013, 310(22): 2435. DOI: 10.1001/jama.2013.280490.
[85]	Xun X J, Yin Q F, Fu Y H, et al. Proton pump inhibitors and the risk of community-acquired pneumonia: an updated meta-analysis[J]. Ann Pharmacother, 2022, 56(5): 524-532.
[86]	Lazarus B, Chen Y, Wilson F P, et al. Proton pump inhibitor use and the risk of chronic kidney disease[J]. JAMA Intern Med, 2016, 176(2): 238. DOI: 10.1001/jamainternmed.2015.7193.
[87]	中华医学会消化病学分会幽门螺杆菌学组. 2022中国幽门螺杆菌感染治疗指南[J]. 胃肠病学, 2022, 27(3):150-162.
[88]	Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the MaastrichtⅥ/Florence consensus report[J]. Gut, 2022, 71(9): 1724-1762. DOI: 10.1136/gutjnl-2022-327745.
[89]	Shah S C, Iyer P G, Moss S F. AGA clinical practice update on the management of refractory Helicobacter pylori infection: expert review[J]. Gastroenterology, 2021, 160(5): 1831-1841.
[90]	Nyssen O P, Perez-Aisa A, Castro-Fernandez M, et al. European Registry on Helicobacter pylori management: single-capsule bismuth quadruple therapy is effective in real-world clinical practice[J]. UEG Journal, 2021, 9(1): 38-46. DOI: 10.1177/2050640620972615.
[91]	Nyssen O P, Mcnicholl A G, Gisbert J P. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori[J]. Helicobacter, 2019, 24(2): e12570. DOI: 10.1111/hel.12570.
[92]	Nyssen O P, Perez-Aisa A, Rodrigo L, et al. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg) [J]. Helicobacter, 2020, 25(5): e12722.
[93]	Zullo A, De Francesco V, Bellesia A, et al. Bismuth-based quadruple therapy following H.pylori eradication failures: a multicenter study in clinical practice[J]. J Gastrointest Liver Dis, 2020, 26(3): 225-229.
[94]	Delchier J C, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori[J]. Aliment Pharmacol Ther, 2014, 40(2): 171-177.
[95]	Muller N, Amiot A, Le Thuaut A, et al. Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains[J]. Clin Res Hepatol Gastroenterol, 2016, 40(4): 517-524.
[96]	Rodríguez De Santiago E, Martín De Argila De Prados C, Marcos Prieto H M, et al. Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera®) in third-line recue treatment for Helicobacter pylori infection. A real-life multicenter study[J]. Helicobacter, 2017, 22(5): e12423. DOI: 10.1111/hel.12423.
[97]	Nyssen O P, Pérez-Aisa Á, Tepes B, et al. Helicobacter pylorifirst-line and rescue treatments in patients allergic to penicillin: experience from the European Registry on H pylori management (Hp-EuReg) [J]. Helicobacter, 2020, 25(3): e12686. DOI: 10.1111/hel.12686.
[98]	Zhou J J, Shi X, Zheng S P, et al. Efficacy of bismuth-based quadruple therapy for eradication of Helicobacter pylori infection based on previous antibiotic exposure: a large-scale prospective, single-center clinical trial in China[J]. Helicobacter, 2020, 25(6): e12755. DOI: 10.1111/hel.12755.
[99]	Mori H, Suzuki H, Matsuzaki J, et al. Acquisition of double mutation in gyrA caused high resistance to sitafloxacin in Helicobacter pylori after unsuccessful eradication with sitafloxacin-containing regimens[J]. U Eur Gastroenterol J, 2018, 6(3): 391-397.
[100]	Mori H, Suzuki H, Matsuzaki J, et al. 10-year trends in Helicobacter pylori eradication rates by sitafloxacin-based third-line rescue therapy[J]. Digestion, 2020, 101(5): 644-650.
[101]	Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses[J]. Aliment Pharmacol Ther, 2005, 22(1): 45-49.
[102]	Gisbert J P. Empirical or susceptibility-guided treatment for Helicobacter pylori infection a comprehensive review[J]. Therap Adv Gastroenterol, 2020, 13: 1756284820968736.
[103]	Savoldi A, Carrara E, Graham D Y, et al. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions[J]. Gastroenterology, 2018, 155(5): 1372-1382.e17. DOI: 10.1053/j.gastro.2018.07.007.
[104]	Huang Y, Chen J N, Ding Z H, et al. Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial[J]. J Gastroenterol, 2023, 58(7): 633-641.
[105]	Zeng S Y, Wang J, Liu J, et al. Efficacy and safety of a 14-day modified concomitant therapy for refractory Helicobacter pylori infection: a pilot study[J]. J Gastro And Hepatol, 2023, 38(12): 2097-2103. DOI: 10.1111/jgh.16348.
[106]	Sue S, Shibata W, Sasaki T, et al. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori[J]. J Gastro And Hepatol, 2019, 34(4): 686-692. DOI: 10.1111/jgh.14456.
[107]	Tanabe H, Yoshino K, Ando K, et al. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication[J]. Ann Clin Microbiol Antimicrob, 2018, 17(1): 29.
[108]	Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phaseⅢ, randomised, double-blind study[J]. Gut, 2016, 65(9): 1439-1446. DOI: 10.1136/gutjnl-2015-311304.
[109]	Furuta T, Yamade M, Kagami T, et al. Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori[J]. Digestion, 2020, 101(6): 743-751.
[110]	中华人民共和国国家卫生健康委员会. 质子泵抑制剂临床应用指导原则(2020年版)[J]. 中国实用乡村医生杂志, 2021, 28(1): 1-9. DOI: 10.3969/j.issn.1672-7185.2021.01.001.
[111]	Ramesh G N, Hunt R, Lazebnik L B, et al. International consensus on guiding recommendations for management of patients with nonsteroidal antiinflammatory drugs induced gastropathy-ICON-G[J]. Eurasian J Hepato Gastroenterol, 2018, 8(2): 148-160.
[112]	Rostom A, Dube C, Wells G A, et al. Prevention of NSAID-induced gastroduodenal ulcers[J]. Cochrane Database Syst Rev, 2002(4): CD002296. DOI: 10.1002/14651858.cd002296.
[113]	Agrawal N M, Campbell D R, Safdi M A, et al. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study[J]. Arch Intern Med, 2000, 160(10): 1455. DOI: 10.1001/archinte.160.10.1455.
[114]	Chey W D, Howden C W, Moss S F, et al. ACG clinical guideline: treatment of Helicobacter pylori infection[J]. Am J Gastroenterol, 2024, 119(9): 1730-1753. DOI: 10.14309/ajg.0000000000002968.
[115]	中华医学会消化病学分会幽门螺杆菌学组. 第六次全国幽门螺杆菌感染处理共识报告(非根除治疗部分)[J]. 胃肠病学, 2022, 27(5): 289-304.
[116]	Hawkey C, Avery A, Coupland C A C, et al. Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2022, 400(10363): 1597-1606. DOI: 10.1016/s0140-6736(22)01843-8.
[117]	Sarri G L, Grigg S E, Yeomans N D. Helicobacter pylori and low-dose aspirin ulcer risk: a meta-analysis[J]. J Gastro and Hepatol, 2019, 34(3): 517-525. DOI: 10.1111/jgh.14539.
[118]	Zhang X, Xiao X, Chen P R, et al. Proton pump inhibitors increase the risk of nonsteroidal anti-inflammatory drug-related small-bowel injury: a systematic review with meta-analysis[J]. Clin Transl Gastroenterol, 2023, 14(6): e00588.
[119]	Washio E, Esaki M, Maehata Y, et al. Proton pump inhibitors increase incidence of nonsteroidal anti-inflammatory drug-induced small bowel injury: a randomized, placebo-controlled trial[J]. Clin Gastroenterol Hepatol, 2016, 14(6): 809-815.e1. DOI: 10.1016/j.cgh.2015.10.022.
[120]	Nadatani Y, Watanabe T, Suda W, et al. Gastric acid inhibitor aggravates indomethacin-induced small intestinal injury via reducing Lactobacillus johnsonii[J]. Sci Rep, 2019, 9: 17490.
[121]	Wallace J L, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis[J]. Gastroenterology, 2011, 141(4): 1314-1322.e5.
[122]	Xiong L S, Huang X X, Li L, et al. Geranylgeranylacetone protects against small-intestinal injuries induced by diclofenac in patients with rheumatic diseases: a prospective randomized study[J]. Dig Liver Dis, 2015, 47(4): 280-284. DOI: 10.1016/j.dld.2015.01.005.
[123]	Niwa Y, Nakamura M, Miyahara R, et al. Geranylgeranylacetone protects against diclofenac-induced gastric and small intestinal mucosal injuries in healthy subjects: a prospective randomized placebo-controlled double-blind cross-over study[J]. Digestion, 2009, 80(4): 260-266. DOI: 10.1159/000236032.
[124]	Nakada K, Hanyu N, Mitsumori N, et al. The usefulness of prokinetics in the treatment of acid-related disease[J]. Nihon Rinsho, 2015, 73(7): 1175-1178.
[125]	许乐. 中国老年人胃食管反流病专家共识(2023)解读[J]. 老年医学与保健, 2023, 29(5): 876-879.
[126]	中华医学会消化病学分会. 2020年中国胃食管反流病专家共识[J]. 中华消化杂志, 2020, 40(10): 649-663. DOI: 10.3760/cma.j.cn311367-20200918-00558.
[127]	Maneerattanaporn M, Pittayanon R, Patcharatrakul T, et al. Thailand guideline 2020 for medical management of gastroesophageal reflux disease[J]. J Gastro and Hepatol, 2022, 37(4): 632-643. DOI: 10.1111/jgh.15758.
[128]	Iwakiri K, Fujiwara Y, Manabe N, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021[J]. J Gastroenterol, 2022, 57(4): 267-285. DOI: 10.1007/s00535-022-01861-z.
[129]	Bor S, Kalkan İ H, Savarino E, et al. Prokinetics-safety and efficacy: the European Society of Neurogastroenterology and Motility/the American Neurogastroenterology and Motility Society expert review[J]. Neurogastroenterology Motil, 2024, 36(5): e14774. DOI: 10.1111/nmo.14774.
[130]	Xi L T, Zhu J Z, Zhang H X, et al. The treatment efficacy of adding prokinetics to PPIs for gastroesophageal reflux disease: a meta-analysis[J]. Esophagus, 2021, 18(1): 144-151.
[131]	Jung D H, Huh C W, Lee S K, et al. A systematic review and meta-analysis of randomized control trials: combination treatment with proton pump inhibitor plus prokinetic for gastroesophageal reflux disease[J]. J Neurogastroenterol Motil, 2021, 27(2): 165-175.
[132]	Ren L H. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis[J]. World J Gastroenterol, 2014, 20(9): 2412. DOI: 10.3748/wjg.v20.i9.2412.
[133]	Zamani N F, Sjahid A S, Tuan Kamauzaman T H, et al. Efficacy and safety of domperidone in combination with proton pump inhibitors in gastroesophageal reflux disease: a systematic review and meta-analysis of randomised controlled trials[J]. J Clin Med, 2022, 11(18): 5268. DOI: 10.3390/jcm11185268.
[134]	Lima J J, Thomas C D, Barbarino J, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing[J]. Clin Pharma and Therapeutics, 2021, 109(6): 1417-1423. DOI: 10.1002/cpt.2015.
[135]	Chevalier R, Attard T, Van Driest S L, et al. A fresh look at proton pump inhibitor (PPI) -associated adverse events through a CYP2C19 pharmacogenetic lens[J]. Expert Opin Drug Metab Toxicol, 2023, 19(2): 53-56. DOI: 10.1080/17425255.2023.2190883.
[136]	Shah S C, Tepler A, Chung C P, et al. Host genetic determinants associated with Helicobacter pylori eradication treatment failure: a systematic review and meta-analysis[J]. Gastroenterology, 2021, 161(5): 1443-1459. DOI: 10.1053/j.gastro.2021.07.043.
[137]	Biswas M, Rahaman S, Biswas T K, et al. Risk of major adverse cardiovascular events for concomitant use of clopidogrel and proton pump inhibitors in patients inheriting CYP2C19 loss-of-function alleles: meta-analysis[J]. Int J Clin Pharm, 2021, 43(5): 1360-1369. DOI: 10.1007/s11096-021-01261-y.
[138]	Abouir K, Exquis N, Gloor Y, et al. Phenoconversion due to drug-drug interactions in CYP2C19 genotyped healthy volunteers[J]. Clin Pharma and Therapeutics, 2024, 116(4): 1121-1129.
[139]	Rohr B S, Krohmer E, Foerster K I, et al. Time course of the interaction between oral short-term ritonavir therapy with three factor xa inhibitors and the activity of CYP2D6, CYP2C19, and CYP3A4 in healthy volunteers[J]. Clin Pharmacokinet, 2024, 63(4): 469-481. DOI: 10.1007/s40262-024-01350-x.
[140]	Mougey E B, Williams A, Coyne A J K, et al. CYP2C19 and STAT6 variants influence the outcome of proton pump inhibitor therapy in pediatric eosinophilic esophagitis[J]. J Pediatr Gastroenterol Nutr, 2019, 69(5): 581-587. DOI: 10.1097/mpg.0000000000002480.
[141]	Ichikawa H, Sugimoto M, Sugimoto K, et al. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis[J]. J Gastro and Hepatol, 2016, 31(4): 716-726. DOI: 10.1111/jgh.13233.
[142]	Wada F, Murase K, Isomoto H, et al. Polymorphism of CYP2C19 and gastric emptying in patients with proton pump inhibitor-resistant gastric ulcers[J]. J Int Med Res, 2002, 30(4): 413-421.
[143]	Smolle K H, Kullnig P, Logar C, et al. Clinical assessment and therapy of barbiturate poisoning (based on 2 case reports)[J]. Wien Klin Wochenschr, 1987, 99(22): 793-798.

药物分类	子类别/代表药物	主要作用机制/特点
抑酸药	（1）H₂受体拮抗剂：西咪替丁、雷尼替丁、法莫替丁、罗沙替丁	阻断胃壁细胞H₂受体，减少胃酸分泌
	（2）PPIs：奥美拉唑、兰索拉唑、泮托拉唑、雷贝拉唑、艾普拉唑、艾司奥美拉唑	抑制H⁺/K⁺-ATP酶，强效抑酸
	（3）P-CAB：富马酸伏诺拉生、替戈拉生、盐酸凯普拉生、戊二酸利那拉生酯	钾离子竞争性酸阻滞剂，快速抑酸且不受进食影响
抗酸药	铝碳酸镁、氢氧化铝、磷酸铝凝胶	直接中和胃酸，快速缓解症状
胃黏膜保护剂	外源性：硫糖铝、铝碳酸镁、枸橼酸铋钾、胶体果胶铋	促进黏液分泌、增加碳酸氢盐含量，物理覆盖保护黏膜
胃黏膜保护剂	内源性：替普瑞酮、瑞巴派特、伊索拉定、依卡倍特钠、聚普瑞锌、胃肠激素类、谷氨酰胺类	稳定细胞膜、增加黏膜保护因子、促进血流、抗氧化，保护胃及小肠黏膜
促动力药	（1）多巴胺D₂受体拮抗剂：多潘立酮；（2）多巴胺D₂受体拮抗剂和乙酰胆碱酯酶抑制剂双重作用：伊托必利；（3）5-HT₄受体激动剂：莫沙必利、普芦卡必利；（4）5-HT₄受体和多巴胺受体双重作用：西尼比利、甲氧氯普胺；（5）阿片肽受体激动剂：曲美布汀；（6）胃动素受体激动剂：红霉素及其衍生物	增强胃肠蠕动、协调运动功能，改善消化不良及胃食管反流
消化酶制剂	胰酶、胃蛋白酶及其复方	补充消化酶，促进食物分解，缓解酶缺乏导致的腹胀、消化不良
TLESR抑制剂	巴氯芬	抑制一过性下食管括约肌松弛（TLESR），减少胃内容物反流
中成药	摩罗丹、枳术宽中胶囊、胃苏颗粒、达立通颗粒、加味左金丸、荜铃胃痛颗粒、荆花胃康胶丸、气滞胃痛颗粒、舒肝解郁胶囊、心胃止痛胶囊、香砂平胃颗粒、香砂养胃丸、香砂六君子颗粒等	调和脾胃、疏肝理气、活血止痛（注：具体机制因药方而异）
神经调节剂	氟哌噻吨美利曲辛、西酞普兰、度洛西汀、舍曲林、帕罗西汀、米氮平、曲唑酮、劳拉西泮等	调节中枢神经功能，改善焦虑抑郁情绪及伴随的胃肠症状
根除Hp抗菌药物	阿莫西林、克拉霉素、四环素、左氧氟沙星、甲硝唑、呋喃唑酮等	联合PPIs和铋剂，根除Hp
止吐药	（1）5-HT₃受体拮抗剂：昂丹司琼等；（2）神经激肽NK₁受体拮抗剂：阿瑞匹坦；（3）5-HT₄受体和多巴胺受体双重作用：甲氧氯普胺；（4）组胺H₁受体拮抗剂：异丙嗪；（5）毒蕈碱M受体拮抗剂：东莨菪碱	通过中枢或外周作用，单药或联合用于预防或治疗常见的急慢性恶心呕吐

药物分类	子类别/代表药物	主要作用机制/特点
抑酸药	（1）H₂受体拮抗剂：西咪替丁、雷尼替丁、法莫替丁、罗沙替丁	阻断胃壁细胞H₂受体，减少胃酸分泌
	（2）PPIs：奥美拉唑、兰索拉唑、泮托拉唑、雷贝拉唑、艾普拉唑、艾司奥美拉唑	抑制H⁺/K⁺-ATP酶，强效抑酸
	（3）P-CAB：富马酸伏诺拉生、替戈拉生、盐酸凯普拉生、戊二酸利那拉生酯	钾离子竞争性酸阻滞剂，快速抑酸且不受进食影响
抗酸药	铝碳酸镁、氢氧化铝、磷酸铝凝胶	直接中和胃酸，快速缓解症状
胃黏膜保护剂	外源性：硫糖铝、铝碳酸镁、枸橼酸铋钾、胶体果胶铋	促进黏液分泌、增加碳酸氢盐含量，物理覆盖保护黏膜
胃黏膜保护剂	内源性：替普瑞酮、瑞巴派特、伊索拉定、依卡倍特钠、聚普瑞锌、胃肠激素类、谷氨酰胺类	稳定细胞膜、增加黏膜保护因子、促进血流、抗氧化，保护胃及小肠黏膜
促动力药	（1）多巴胺D₂受体拮抗剂：多潘立酮；（2）多巴胺D₂受体拮抗剂和乙酰胆碱酯酶抑制剂双重作用：伊托必利；（3）5-HT₄受体激动剂：莫沙必利、普芦卡必利；（4）5-HT₄受体和多巴胺受体双重作用：西尼比利、甲氧氯普胺；（5）阿片肽受体激动剂：曲美布汀；（6）胃动素受体激动剂：红霉素及其衍生物	增强胃肠蠕动、协调运动功能，改善消化不良及胃食管反流
消化酶制剂	胰酶、胃蛋白酶及其复方	补充消化酶，促进食物分解，缓解酶缺乏导致的腹胀、消化不良
TLESR抑制剂	巴氯芬	抑制一过性下食管括约肌松弛（TLESR），减少胃内容物反流
中成药	摩罗丹、枳术宽中胶囊、胃苏颗粒、达立通颗粒、加味左金丸、荜铃胃痛颗粒、荆花胃康胶丸、气滞胃痛颗粒、舒肝解郁胶囊、心胃止痛胶囊、香砂平胃颗粒、香砂养胃丸、香砂六君子颗粒等	调和脾胃、疏肝理气、活血止痛（注：具体机制因药方而异）
神经调节剂	氟哌噻吨美利曲辛、西酞普兰、度洛西汀、舍曲林、帕罗西汀、米氮平、曲唑酮、劳拉西泮等	调节中枢神经功能，改善焦虑抑郁情绪及伴随的胃肠症状
根除Hp抗菌药物	阿莫西林、克拉霉素、四环素、左氧氟沙星、甲硝唑、呋喃唑酮等	联合PPIs和铋剂，根除Hp
止吐药	（1）5-HT₃受体拮抗剂：昂丹司琼等；（2）神经激肽NK₁受体拮抗剂：阿瑞匹坦；（3）5-HT₄受体和多巴胺受体双重作用：甲氧氯普胺；（4）组胺H₁受体拮抗剂：异丙嗪；（5）毒蕈碱M受体拮抗剂：东莨菪碱	通过中枢或外周作用，单药或联合用于预防或治疗常见的急慢性恶心呕吐

指标类别	一级药学监护	二级药学监护	三级药学监护^a
病理生理状态
特殊生理状态	符合以下任意一项，进行一级药学监护：（1）妊娠或哺乳期女性；（2）新生儿或婴幼儿（≤3岁）	符合以下任意一项，进行二级药学监护：（1）儿童（>3岁，≤18岁）或老年（≥65岁）；（2）吞咽困难或禁食状态	体质量异常^[26]（BMI<18.5 kg/m²或BMI≥28.0 kg/m²）
特殊病理状态	符合以下任意一项，进行一级药学监护：（1）重度感染；（2）呕血、血便或活动性出血；（3）循环衰竭、呼吸衰竭、意识障碍、误吸或GBS评分>1分中任意一项；（4）肝硬化或重度肝、肾功能不全^b；（5）合并严重创伤、手术等应激状态^c；（6）ICU等重症科室转诊患者	符合以下任意一项，进行二级药学监护：（1）合并其他基础疾病，病情不稳定（例如GERD洛杉矶分级C~D级）；（2）中度感染；（3）接受全肠外营养支持或管饲肠内营养支持；（4）营养风险筛查（NRS-2002）≥3分；（5）黑便或内镜下观察到少量出血；（6）凝血功能障碍（INR>1.5）；（7）中度肝、肾功能不全；（8）合并睡眠障碍或需要精神心理治疗干预；（9）既往Hp根除失败	（1）轻度感染；（2）粪便隐血阳性；（3）轻度肝、肾功能不全
药物治疗情况
酸相关疾病用药风险	符合以下任意一项，进行一级药学监护：（1）用药品种数^[23]≥10种；（2）抑酸剂或抗酸剂使用双倍以上治疗剂量；（3）发生有临床意义的药物相互作用；（4）有药物不良反应，CTCAE 4~5级	符合以下任意一项，进行二级药学监护：（1）5种≤用药品种数^[23] <10种；（2）存在相似作用机制药物的联合使用；（3）抑酸剂或抗酸剂使用双倍治疗剂量；（4）有药物不良反应，CTCAE 2~3级；（5）长期使用或住院期间合并使用糖皮质激素、非甾体抗炎药、抗血小板药物、双膦酸盐、免疫抑制剂、化疗药等对消化道黏膜屏障破坏作用的药物	（1）仅有潜在的药物相互作用；（2）药物不良反应轻微，如CTCAE 1级
合理用药管控	参考所在医疗机构相关管控指标^d

指标类别	一级药学监护	二级药学监护	三级药学监护^a
病理生理状态
特殊生理状态	符合以下任意一项，进行一级药学监护：（1）妊娠或哺乳期女性；（2）新生儿或婴幼儿（≤3岁）	符合以下任意一项，进行二级药学监护：（1）儿童（>3岁，≤18岁）或老年（≥65岁）；（2）吞咽困难或禁食状态	体质量异常^[26]（BMI<18.5 kg/m²或BMI≥28.0 kg/m²）
特殊病理状态	符合以下任意一项，进行一级药学监护：（1）重度感染；（2）呕血、血便或活动性出血；（3）循环衰竭、呼吸衰竭、意识障碍、误吸或GBS评分>1分中任意一项；（4）肝硬化或重度肝、肾功能不全^b；（5）合并严重创伤、手术等应激状态^c；（6）ICU等重症科室转诊患者	符合以下任意一项，进行二级药学监护：（1）合并其他基础疾病，病情不稳定（例如GERD洛杉矶分级C~D级）；（2）中度感染；（3）接受全肠外营养支持或管饲肠内营养支持；（4）营养风险筛查（NRS-2002）≥3分；（5）黑便或内镜下观察到少量出血；（6）凝血功能障碍（INR>1.5）；（7）中度肝、肾功能不全；（8）合并睡眠障碍或需要精神心理治疗干预；（9）既往Hp根除失败	（1）轻度感染；（2）粪便隐血阳性；（3）轻度肝、肾功能不全
药物治疗情况
酸相关疾病用药风险	符合以下任意一项，进行一级药学监护：（1）用药品种数^[23]≥10种；（2）抑酸剂或抗酸剂使用双倍以上治疗剂量；（3）发生有临床意义的药物相互作用；（4）有药物不良反应，CTCAE 4~5级	符合以下任意一项，进行二级药学监护：（1）5种≤用药品种数^[23] <10种；（2）存在相似作用机制药物的联合使用；（3）抑酸剂或抗酸剂使用双倍治疗剂量；（4）有药物不良反应，CTCAE 2~3级；（5）长期使用或住院期间合并使用糖皮质激素、非甾体抗炎药、抗血小板药物、双膦酸盐、免疫抑制剂、化疗药等对消化道黏膜屏障破坏作用的药物	（1）仅有潜在的药物相互作用；（2）药物不良反应轻微，如CTCAE 1级
合理用药管控	参考所在医疗机构相关管控指标^d

监护项目	条目	一级监护	二级监护	三级监护
药学问诊	时间	入院/转诊或病情变化时
药学查房/过程监护	频次	≥3次/周	≥2次/周	≥1次/周
药学查房/过程监护	项目	医嘱审核用药干预病例讨论/会诊	医嘱审核用药干预	医嘱审核
用药咨询/用药教育	时间	出院前/必要时